In an exciting corporate and trading update, Ondine Biomedical Inc., a global leader in the provision of light-activated antimicrobial technology, has announced significant revenue growth and continued commercial momentum in their endeavor to combat hospital infections. In 2023, revenues almost doubled, reaching $1.2 million, primarily driven by the escalating number of hospitals implementing Steriwave®, Ondine’s innovative technology solution. This growth pattern extended into the first quarter of 2024, with eight additional hospital deployments reflecting a 50% hike compared to the previous year-end.
Earlier this year, Ondine expanded its hospital network with five new international placements, making significant strategic inroads into the UK’s National Health Service (NHS). This was largely propelled by strong pilot data and the enthusiastic adoption of Steriwave® by healthcare professionals and patients alike. Ondine continues its overseas success with rollouts in Spain and Australia. Back home, the company’s ongoing collaborations with potential distribution partners promise to ramp up commercial momentum and increase geographical reach.
Taking advantage of the growing interest in alternatives to the commonly used antibiotic mupirocin, Ondine plans to enter the Intensive Care Unit (ICU) market. Mupirocin requires extensive administration times and fosters antibiotic resistance, and Steriwave® is posited as a viable alternative. Considering the high rates of infections in ICUs, this expansion presents a significant opportunity for the company. Launching Steriwave® into ICUs also enables Ondine to fulfill an unmet need in the healthcare sector, as it can improve patient outcomes while reducing both the cost and duration of care.
A significant development has been the finalization of the design and budget for the US Phase 3 Clinical Trial plans. Set to commence in Q3 of 2024, the trial will compare Ondine’s nasal photodisinfection added to standard-of-care infection prevention practices against standard-of-care alone. Optimistically, the data from the trial will expedite FDA approval, facilitating the adoption of Steriwave® in the US. Notably, Ondine has been attracting substantial support for its growth and expansion endeavors from its founder CEO, and existing shareholders, among others.
As a pioneer in light-activated antimicrobial therapies, Ondine Biomedical Inc. constantly innovates and develops products. One such example is the Steriwave® nasal photodisinfection system, a patented technology that destroys nasal bacteria, viruses, and fungi using a light-activated antimicrobial. Considered a key advancement in the field, Steriwave® offers effective resistance against drug-resistant pathogens – a bonus over conventional antibiotics.
Source: https://www.accesswire.com/856026/ondine-biomedical-inc-announces-corporate-and-trading-update